Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Exclusive interview with Jörg König on Drug Transporters and HEK


Published on

In an exclusive interview, PD Dr. Jörg König from the Institute for Experimental and Clinical Pharmacology and Clinical Toxicology, Friedrich-Alexander-University Erlangen-Nürnberg, Germany talks about the latest developments of pharmacogenetics of drug transporters. PD Dr König also responds to questions such as What are the advantages and disadvantages of Human Embryonic Kidney (HEK) cells for the analysis of uptake transporters?

--> Listen to the full interview here:

Since 2005, PD Dr Jörg König’s focus has been on pharmacogenetics of drug transporters and characterization of the functional consequences of polymorphisms in transporter genes. He also specializes in analyzing the role of transport proteins in drug-drug-interactions using in vitro cell models, and in vitro – in vivo extrapolation (IVIVE) of transporter data.

Questions answered in this exclusive interview include:

1.) Which cell systems do you rotinely use for the analysis of transporter-mediated drug-drug interactions, what are the advantages and disadvantages?

2.) What are the different kinds of transporter-mediated drug-drug interactions?

3.) What about the transferability of in vitro generated transport- and inhibition data to the in vivo situation, the so called in vitro in vivo extrapolation?

4.) What do you think about the importance of genetic variations, polymorphisms and haplotypes in transporter genes for drug treatment?

--> Listen to the full interview here:

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this